Opinions Gordon Reid
Biogen IDEC Inc.BIIBTOP PICKMar 16, 2017
Gordon ReidStock price when the opinion was issued
As of Jun 05, 2026. Market Open.
You might be interested:
;fill-opacity:1;'/%3e%3cpath%20d='M31%2018.6001V30H8V18.6001L14.1334%2022.4334L19.4999%2014L24.8669%2022.4334L31%2018.6001Z'%20fill='%23EE5432'%20style='fill:%23EE5432;fill:color(display-p3%200.9340%200.3310%200.1956);fill-opacity:1;'/%3e%3c/svg%3e){kind=small}
Premium content
Premium contentPremium content(A Top Pick Nov 26/20, Up 26.1%)Stochchase Research Editor: Michael O'Reilly Our PAST TOP PICK with CIEN has gapped up through the $305 target. To be disciplined, we recommend trailing up the stop (from $180) to $305. If triggered, this would all but guarantee a minimum investment return over 26%.
Premium contentStockchase Research Editor: Michael O'Reilly BIIB has been on a roller-coaster. When the FDA announced a priority review of a new Alzheimer's drug, it stock soared to $360. When the review failed to approve the drug in the first go-round, the stock plunged to under $250 -- so it goes with drug manufacturers. Its MS drugs continue to do well and it is working on treatments for Parkinson's disease as well. Trading at 8x earnings, it is cheap compared to peers at 30x. We would buy this with a $180 stop-loss looking to achieve $305 -- 26% upside. Yield 0%. (Analysts’ price target is $305.90)
https://www.pmlive.com/pharma_news/fda_sets_november_date_for_expert_panel_review_of_biogens_aducanumab_1351831 Until February 2020, Biogen's FDA results of an Alzheimer drug was the healthcare event of the year (then Covid hit). Novartis and other players are starting to compete here, though. He owned Biogen some years ago. He was on a panel which was split over whether Biogen would get FDA approval on Nov. 6. Regardless, this is a high-risk play; this could pop 35-50% up or down. The risk/return is too much for him. The drug has a checkered past and so far there is no effective Alzheimer's drug, but if it works it will be huge for the company and society.
Jason Del Vicario
A bio pharmaceutical. If you look at the traditional Pharma space, the chemical-based companies, the bio-based companies were always out there, coming along, but basically not making a lot of money and were often single drug companies, virtually reinvesting all their cash flow. They have now matured and into much stronger growth companies than the traditional pharmas. They also have lower multiples than they did 5-6 years ago. That makes it quite attractive. (Analysts’ price target is $305.)